tAPC + STING agonist

tAPC + STING agonist refers to an investigational **combination immunotherapy** in which therapeutic antigen-presenting cells (tAPCs, typically ex vivo–manipulated dendritic cells or other professional APCs) are administered together with a small‑molecule or cyclic‑dinucleotide STING agonist to enhance antitumor or antiviral immunity. In this strategy, the STING agonist activates the cGAS–STING pathway in antigen-presenting cells, driving type I interferon and proinflammatory cytokine production, dendritic cell maturation, and potent cross‑priming of cytotoxic T cells, while the tAPCs provide optimized antigen presentation and co‑stimulation to shape a strong, antigen‑specific T‑cell response.[3][5][7] The combination is conceptually positioned for oncology and potentially infectious‑disease immunotherapy, but specific proprietary products, developers, or clinical programs under the exact name “tAPC + STING agonist” are not clearly identified in the public domain.